Whilst the exploiting of this therapeutic modality surges through biopharma and academia, it is essential that we unlock the fundamental challenges within this industry, as this remains a key factor determining success of degraders in the clinic.

The 2nd Ligase Targeting Drug Development Summit returns to Boston in April again uniting industry frontiers and leading minds, as together we discuss, update, and learn how to successfully hijack ligases for therapeutic application, and uncover a critical piece of the puzzle in realizing the full potential of this therapeutic approach.

Filling the gap of an industry-led ubiquitin discussion, we again provide an unrivalled forum to unite leading biopharmaceutical giants, alongside key academics, to share unseen data, collaborative efforts and discuss next steps to successfully select, validate and translate E3’s into a viable therapy.

Join us in Boston to expand your understanding of the ever-broadening ligases field and the fast-improving chemical biology tools to seize the therapeutic value of Ubiquitin E3 ligases and differentiate your pipelines.

To Know more visit: https://ter.li/rm8y7d